lilly glp-1 drugs FDA approves new weight-loss pill, Foundayo Orforglipron: Eli Lilly's New Oral

Then feel stronger, more in control, and more consistent over 34 months of daily use.* SUPPORT APPETITE, ENERGY, AND MOTIVATION NATURALLY: Feel fuller longer without feeling forced

AstraZeneca, Novo Nordisk A/S, Eli Lilly and Company, Sanofi and Hypera S.A

The Medicines and Healthcare products Regulatory Agency (MHRA) has warned healthcare professionals to be aware of the potential risk of pulmonary aspiration in patients using glucagon-like peptide-1 (GLP-1) or dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists (GLP-1 RAs), who undergo surgery or procedures with general anaesthesia or deep sedation

Co-medication analysis revealed 81 cases with antidepressants, antipsychotics, and benzodiazepines, which may be proxies of mental health comorbidities

The messaging is about affordability and access

Our blog series on GLP-1 agonists for weight loss is aimed at unpacking the science behind this new frontier in weight management, presenting a detailed overview of how they work, their efficacy, and their role in a holistic approach to health and wellness.